A meta-analysis of 1.6 million people found no raised psychiatric risk from isotretinoin

At a population level, people who take isotretinoin for acne do not have a higher risk of suicide or psychiatric illness than people who do not. That is the finding of a meta-analysis of 25 studies covering 1,625,891 participants — and it comes with an unexpected complication: users were slightly less likely to attempt suicide in the two to four years following treatment than non-users, and the analysis cannot explain why.

What was measured

The review searched PubMed, Embase, Web of Science and Scopus from inception to 24 January 2023 for randomised trials and observational studies reporting absolute risk, relative risk or risk factors for suicide and psychiatric disorders among isotretinoin users [s1]. Twenty-five studies were included in the review and 24 in the meta-analysis, with participants' average ages ranging from 16 to 38 years across studies and the proportion male ranging from 0% to 100% [s1].

The one-year absolute risks were low. Pooled across between two and eight studies each, completed suicide, suicide attempt, suicidal ideation and self-harm were each below 0.5% among isotretinoin users [s1]. Depression, pooled across 11 studies, ran at 3.83% (95% confidence interval 2.45 to 5.93), with heterogeneity of 77% [s1].

On relative risk, isotretinoin was not associated with psychiatric disorders taken as a whole: 1.08 (0.99 to 1.19), with no heterogeneity between studies [s1]. And for suicide attempts, users came out below non-users at two years (0.92, 0.84 to 1.00), three years (0.86, 0.77 to 0.95) and four years (0.85, 0.72 to 1.00) [s1]. Two of those three intervals touch or cross 1.00; the three-year estimate does not.

Two patterns emerged from meta-regression across studies. Studies with older participants reported a lower one-year absolute risk of depression, and studies with a higher proportion of male participants reported a higher one-year absolute risk of completed suicide [s1].

Why a protective-looking result is not proof of protection

The most likely explanation for users faring better is not that the drug improves mood but that severe acne worsens it, and treating the acne removes the cause. That reading is consistent with what is known about the condition: acne is associated with depression, anxiety, unemployment and productivity loss [s3]. But the meta-analysis pools observational studies, and observational studies of a prescription drug carry a structural problem in both directions — the people who get prescribed isotretinoin differ from those who do not, and in most jurisdictions prescribing guidance already directs clinicians to screen for and monitor mental health before and during treatment.

That screening, if it works, would tend to keep the highest-risk patients out of the treated group. A protective association could therefore reflect the safety system around the drug rather than the drug. The paper does not claim otherwise. Its stated conclusion is that at a population level isotretinoin users do not have increased risk, "but may instead have a lower risk of suicide attempts at 2 to 4 years following treatment", and that while the findings are reassuring, clinicians should continue holistic psychodermatologic care and monitor patients for signs of mental distress during treatment [s1].

The warning that remains

The US Food and Drug Administration issued a boxed warning for suicide, depression, aggression and psychosis in 2005 [s1]. Nothing in this meta-analysis removes it, and the analysis is not designed to. A population-level null result is compatible with individual reactions that are real and rare — a 1-in-10,000 event would not be visible in a pooled relative risk of 1.08 across a million and a half people, and none of the included studies were built to detect one.

The proposed biological mechanism behind the concern is that isotretinoin may alter levels of neurotransmitters involved in mood regulation, including dopamine, serotonin and norepinephrine [s1]. That hypothesis is not tested by epidemiology of this kind; it is the reason the epidemiology was thought worth doing.

Where the drug sits clinically

The American Academy of Dermatology's acne guideline strongly recommends oral isotretinoin for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy [s2]. "Causing psychosocial burden" is doing quiet work in that sentence: the guideline treats the mental-health consequences of untreated acne as an indication for the drug whose mental-health effects are under debate.

That is the tension a reader should carry away. The strongest available epidemiology finds no excess psychiatric risk and a small apparent reduction in suicide attempts. The regulatory warning stands because population data cannot rule out rare individual reactions. And the condition being treated is itself associated with depression and anxiety, which makes the counterfactual — what would have happened to these patients untreated — the hardest thing in the whole question to observe.

This article is informational and is not medical advice. Isotretinoin carries a range of serious requirements and contraindications, including in pregnancy, that are not covered here.

Sources

• [s1] Risk of Suicide and Psychiatric Disorders Among Isotretinoin Users: A Meta-Analysis — JAMA Dermatology, published online 29 November 2023. https://doi.org/10.1001/jamadermatol.2023.4579
• [s2] Guidelines of care for the management of acne vulgaris — Journal of the American Academy of Dermatology, 30 January 2024. https://doi.org/10.1016/j.jaad.2023.12.017
• [s3] The mediterranean diet and acne vulgaris: a systematic review and meta-analysis — Nutrition & Metabolism, 5 November 2025. https://doi.org/10.1186/s12986-025-01033-9